| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1999PNAS...96.5722L |
| P356 | DOI | 10.1073/PNAS.96.10.5722 |
| P932 | PMC publication ID | 21927 |
| P698 | PubMed publication ID | 10318951 |
| P5875 | ResearchGate publication ID | 12979609 |
| P50 | author | Kin-Mang Lau | Q58469938 |
| P2093 | author name string | S C Mok | |
| S M Ho | |||
| P2860 | cites work | ER beta: identification and characterization of a novel human estrogen receptor | Q24317610 |
| Cloning of a novel receptor expressed in rat prostate and ovary | Q24607949 | ||
| Expression of estrogen receptor beta messenger RNA variant in breast cancer | Q28259978 | ||
| Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues | Q28264982 | ||
| Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta | Q28304508 | ||
| Responses in the brain of estrogen receptor alpha-disrupted mice | Q36604561 | ||
| Endocrine Factors in Common Epithelial Ovarian Cancer* | Q37176622 | ||
| Does HRT modify risk of gynecological cancers? | Q39479229 | ||
| Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. | Q40949679 | ||
| SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens | Q41265574 | ||
| Estrogen action in human ovarian cancer | Q41457706 | ||
| Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action | Q41546396 | ||
| Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix | Q41606674 | ||
| Cloning of the rat progesterone receptor gene 5'-region and identification of two functionally distinct promoters | Q42804329 | ||
| Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). | Q42805879 | ||
| Human chorionic gonadotropin, follicle-stimulating hormone, and luteinizing hormone in patients with epithelial ovarian carcinoma | Q44026933 | ||
| Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. | Q46193488 | ||
| Exploring the role of sex steroids through studies of receptor deficient mice | Q47861980 | ||
| Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling | Q47997907 | ||
| Estrogen receptor mutations in tamoxifen-resistant breast cancer | Q48085724 | ||
| Plasma level of estradiol in patients with ovarian malignant tumors. | Q51770095 | ||
| Testosterone, SHBG and albumin in patients with ovarian carcinoma. | Q51815599 | ||
| Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. | Q52196619 | ||
| Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. | Q52519614 | ||
| Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen | Q67446195 | ||
| Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer | Q68568858 | ||
| Ovarian and peripheral androgen and oestrogen levels in post-menopausal women: correlations with ovarian histology | Q69497452 | ||
| Elevated progesterone levels in serum and ovarian venous blood in patients with ovarian tumors | Q69791021 | ||
| Gonadal steroids, gonadotropins and endometrial histology in postmenopausal women with malignant ovarian tumors | Q70301050 | ||
| Ovarian and peripheral plasma levels of progestogens, androgens and oestrogens in post-menopausal women | Q70596141 | ||
| Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women | Q70667848 | ||
| Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade | Q71763510 | ||
| Estrogen replacement therapy and fatal ovarian cancer | Q72157255 | ||
| Aging and development of ovarian epithelial carcinoma: the relevance of changes in ovarian stromal androgen production | Q72917090 | ||
| An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer | Q73221160 | ||
| Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines | Q73335132 | ||
| Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats | Q74013327 | ||
| A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors | Q74178345 | ||
| Cancer incidence in a cohort of infertile women | Q74628783 | ||
| Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis | Q77168041 | ||
| Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells | Q77227947 | ||
| Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas | Q77556510 | ||
| Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone | Q77636062 | ||
| Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis | Q77670035 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 5722-5727 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells | |
| P478 | volume | 96 |
| Q38766965 | 17 β-Estradiol Reverses Leptin-Inducing Ovarian Cancer Cell Migration by the PI3K/Akt Signaling Pathway |
| Q54859210 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation. |
| Q33642960 | A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor |
| Q49359257 | A computational based approach to identify estrogen receptor alpha/beta heterodimer selective ligands |
| Q43755070 | Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential |
| Q36840255 | Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer |
| Q39028384 | Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens |
| Q36447431 | Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues |
| Q40749668 | Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. |
| Q37194722 | An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells |
| Q34345107 | Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk |
| Q39188061 | Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression |
| Q24791470 | Animal models of ovarian cancer |
| Q34556898 | Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers |
| Q36152737 | Bisphenol A and hormone-associated cancers: current progress and perspectives |
| Q34608699 | Characterization of ascites-derived ovarian tumor cells from spontaneously occurring ovarian tumors of the chicken: evidence for E-cadherin upregulation |
| Q42487014 | Characterization of calcium-mobilizing, purinergic P2Y(2) receptors in human ovarian cancer cells |
| Q34062570 | Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers |
| Q38864663 | Cisplatin-, Doxorubicin-, and Docetaxel-Induced Cell Death Promoted by the Aqueous Extract of Solanum nigrum in Human Ovarian Carcinoma Cells. |
| Q37424155 | Combined application of 17beta-estradiol and progesterone enhance vascular endothelial growth factor and surfactant protein expression in cultured embryonic lung cells of mice |
| Q33767047 | DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma |
| Q34595670 | Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma |
| Q38363908 | Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors |
| Q34546378 | Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression |
| Q58325237 | Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling |
| Q37143825 | Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling? |
| Q43790618 | ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. |
| Q35855100 | Early alterations in ovarian surface epithelial cells and induction of ovarian epithelial tumors triggered by loss of FSH receptor |
| Q38873842 | Effects of bisphenol A and 17β-estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines. |
| Q36665020 | Emerging significance of ER-coregulator PELP1/MNAR in cancer |
| Q92702483 | Epigenetic Dysregulation at the Crossroad of Women's Cancer |
| Q37332214 | Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells |
| Q40790462 | Establishment and characterization of an immortalized human oviductal cell line. |
| Q37379821 | Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells |
| Q34249388 | Estrogen and androgen receptor expression in surface epithelium and inclusion cyst in the ovary of premenopausal and postmenopausal women |
| Q89842725 | Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3 |
| Q28109453 | Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy |
| Q35929364 | Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis |
| Q33642747 | Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. |
| Q34022694 | Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer |
| Q73566195 | Estrogen stimulation of ovarian surface epithelial cell proliferation |
| Q24805637 | Estrogen, progesterone and epithelial ovarian cancer |
| Q46418281 | Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells |
| Q35840390 | Estrogens and epithelial ovarian cancer |
| Q34579904 | Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma |
| Q34056207 | Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer |
| Q43545822 | Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids |
| Q40446182 | Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells |
| Q53482030 | Expression of gonadal steroid receptors in the ovaries of post-menopausal women with malignant or benign endometrial pathology: a pilot study. |
| Q34200707 | Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events |
| Q34223682 | Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma |
| Q45274570 | Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer |
| Q46403948 | Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas |
| Q58710004 | Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer |
| Q57492362 | Fertility Enhancement but Premature Ovarian Failure in -Deficient Female Zebrafish |
| Q37091852 | Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer |
| Q36583705 | Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators. |
| Q37035786 | Gonadotropin-releasing hormone in the ovary |
| Q33820206 | HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation |
| Q40779150 | High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane |
| Q37624838 | Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression |
| Q33647661 | Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer |
| Q26751021 | Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations |
| Q80552811 | Hormone replacement therapy and ovarian cancer risk: a meta-analysis |
| Q36966197 | Hormone response in ovarian cancer: time to reconsider as a clinical target? |
| Q46232798 | Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro |
| Q35787316 | Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance |
| Q78454473 | IL-1alpha gene expression in human endometrial cancer is independent of ovarian steroid receptor expression |
| Q28304574 | Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling |
| Q34577355 | Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework. |
| Q96952577 | Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice |
| Q33986711 | Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival |
| Q36948026 | Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines |
| Q33963529 | Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells |
| Q36413695 | Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor |
| Q35600183 | Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy |
| Q35888377 | Loss of ERbeta expression as a common step in estrogen-dependent tumor progression |
| Q97539631 | Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors |
| Q92071291 | Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis |
| Q43864747 | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition |
| Q36643725 | Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines |
| Q37888659 | Molecular targeted therapy in ovarian cancer: what is on the horizon? |
| Q90317700 | Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions |
| Q35620640 | Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition |
| Q35552356 | Ovarian cancer and high-risk women—implications for prevention, screening, and early detection |
| Q35983656 | Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis |
| Q35178056 | Preclinical evaluation on the tumor suppression efficiency and combination drug effects of fermented wheat germ extract in human ovarian carcinoma cells |
| Q38321797 | Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. |
| Q46141026 | Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients |
| Q33829679 | Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis |
| Q53367630 | Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. |
| Q33623349 | Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study |
| Q43597404 | Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones |
| Q34764768 | Risk factors for ovarian cancer: an overview with emphasis on hormonal factors |
| Q36703049 | Role of endocrine and growth factors on the ovarian surface epithelium. |
| Q39915688 | ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function |
| Q36243394 | Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
| Q38939445 | Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides |
| Q38320209 | Structurally similar estradiol analogs uniquely alter the regulation of intracellular signaling pathways |
| Q50107365 | Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality |
| Q39268041 | Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway |
| Q64245953 | The Role of Androgen Receptor Signaling in Ovarian Cancer |
| Q39309057 | The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status |
| Q37695280 | The carcinogenicity of dietary acrylamide intake: a comparative discussion of epidemiological and experimental animal research. |
| Q35646553 | The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis |
| Q36623704 | The human ovarian surface epithelium is an androgen responsive tissue |
| Q73135110 | The oestrogen receptor (ER) in vulva, vagina and ovary |
| Q36169983 | The progesterone receptor PROGINS polymorphism is not related to oxidative stress factors in women with polycystic ovary syndrome |
| Q36796735 | The role of activin A and Akt/GSK signaling in ovarian tumor biology |
| Q26786826 | The role of reproductive hormones in epithelial ovarian carcinogenesis |
| Q24316645 | Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition |
| Q46545456 | Tumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia--an array study on case-specific human preeclamptic placental tissue |
| Q24815527 | WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome |
Search more.